At BIO Asia–Taiwan’s Day 2 Innovation Forum A-6, experts from AB Biosciences, OBI Pharma, and Nanocarry Therapeutics unveiled cutting-edge antibody innovations:

Dr. Yen-Ming Hsu, Founder of AB Biosciences, introduced PRIM proteins—a potential IVIG alternative with strong anti-inflammatory effects. AI-supported development is underway.

OBI Pharma revealed its GlycOBI® next-gen ADC platform—dual payload + bispecific design for enhanced cancer treatment precision.

Dr. Oshra Betzer, Co-founder of Nanocarry, showcased AxS, a nanotech platform that crosses the blood-brain barrier to deliver antibodies directly to the brain.

Read more: https://reurl.cc/z5ZVRQ

#Globalbio #AntibodyTech #ADC #Neuroscience #ProteinTherapeutics #BIOAsiaTaiwan